Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

702
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
702
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

249
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
249
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

T-cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT.

Bone marrow transplantation·2026
Same author

Optimizing CAR-T therapy delivery in the Italian healthcare system: economic and organizational insights in follicular lymphoma.

Global & regional health technology assessment·2026
Same author

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

Bone marrow transplantation·2026
Same author

Targeted Screening to Predict <i>Magnusiomyces</i> Infections in Hematopoietic Cell Transplant Recipients: Evidence from an Outbreak Setting.

Journal of fungi (Basel, Switzerland)·2026
Same author

Late outcomes after posttransplant cyclophosphamide-based GVHD prophylaxis in patients with AML: an ALWP-EBMT study.

Blood neoplasia·2026
Same author

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real-Life Multicenter Experience. Results From the REDOT_MCL Study.

Hematological oncology·2026

Related Experiment Video

Updated: Sep 30, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.9K

CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma.

Massimiliano Gambella1,2, Simona Carlomagno2, Anna Maria Raiola1

  • 1Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Frontiers in Immunology
|March 14, 2022
PubMed
Summary

Cancer immunotherapies, including CAR T-cell and NK cell therapies, offer new hope for Diffuse Large B-cell Lymphoma (DLBCL) patients. This review highlights CD19-targeted treatments and future clinical opportunities.

Keywords:
CAR-NK cellsCAR-T cellsantibody-drug conjugatesbispecific T cell engagersengineered T cellsgenetic modificationmonoclonal antibodies

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Related Experiment Videos

Last Updated: Sep 30, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.9K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Area of Science:

  • Oncology
  • Immunology
  • Cell Therapy

Background:

  • Traditional cancer treatments like surgery, chemotherapy, and radiotherapy are being complemented by novel immunotherapies.
  • Cancer immunotherapies leverage the patient's immune system to target and eliminate cancer cells.
  • Recent advancements include adoptive cell therapies using genetically modified T cells and Natural Killer (NK) cells.

Purpose of the Study:

  • To review the latest advancements in immunotherapies for Diffuse Large B-cell Lymphoma (DLBCL).
  • To focus on the progress of CD19-targeted immunotherapies in DLBCL treatment.
  • To discuss ongoing clinical trials and future prospects for immunotherapy in DLBCL.

Main Methods:

  • Review of preclinical and clinical studies on adoptive cell therapies.
  • Focus on chimeric antigen receptor (CAR) engineered T cells and NK cells.
  • Analysis of CD19-targeted strategies in DLBCL.

Main Results:

  • Adoptive cell therapies, particularly CAR T-cell therapies, have demonstrated significant efficacy in DLBCL.
  • CD19-targeted immunotherapies show promise as a leading treatment modality.
  • Ongoing research is expanding the application of these therapies.

Conclusions:

  • Immunotherapies represent a significant advancement in DLBCL treatment beyond conventional methods.
  • CD19-targeted approaches are crucial for effective immunotherapy in DLBCL.
  • Further clinical trials are essential to optimize and broaden the use of immunotherapies for DLBCL patients.